Skip to content
MarketScale
‹ Back to IndustriesSciences

With New Research into Hot Flashes During Menopause, Scientists Expand Treatment Options for Women’s Health

Hot flashes during menopause, a common symptom of women’s natural midlife biology, affect more than 80% of women. The causes behind these common hot flashes have remained a mystery to scientists for years. However, recent research has revealed a breakthrough in understanding the root cause of these uncomfortable, sweaty episodes. Researchers from The Queen’s Medical…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Sciences · EstrogenHormone TherapyHot FlashesMenopause
Share

Key takeaways

01

Hot flashes during menopause, a common symptom of women’s natural midlife biology, affect more than 80% of women.

02

The causes behind these common hot flashes have remained a mystery to scientists for years.

03

However, recent research has revealed a breakthrough in understanding the root cause of these uncomfortable, sweaty episodes.

Hot flashes during menopause, a common symptom of women’s natural midlife biology, affect more than 80% of women. The causes behind these common hot flashes have remained a mystery to scientists for years. However, recent research has revealed a breakthrough in understanding the root cause of these uncomfortable, sweaty episodes.

Researchers from The Queen’s Medical Research Institute, the Mayo Clinic’s Center for Translational Science Activities, the Institute for Infectious Diseases and Molecular Medicine at the University of Cape Town, among others, have discovered the root cause of hot flashes is actually non-hormonal. They identified that a particular group of neurons in the brain become activated during menopause, which can cause temperature regulation disturbances leading to hot flashes. The activation of these neurons is due to the decrease of estrogen in the brain’s hypothalamus during menopause.

This discovery is one of many helping scientists better understand the root causes and side effects of menopause. Perhaps the most important consequence of this deeper understanding of hot flashes is that it gives women and their doctors a better framework for understanding the role of hormonal therapy in treating symptoms of menopause.

Much skepticism still surrounds hormone therapy for treating hot flashes during menopause and other menopause symptoms. One 2022 study found links between hormone therapy and increased risks of breast cancer and other health conditions. Other studies showed that the benefits of hormone therapy greatly outweigh the risks. Regardless, the most recent developments around the causes behind hot flashes are providing hope for new, non-hormonal, and perhaps better treatments. One drug, fezolinetant, is a non-hormonal treatment for hot flashes currently under review by the U.S. FDA; the most recent round of clinical trials for the drug found it “reduced the frequency and severity of moderate-to-severe vasomotor symptoms,” otherwise known as hot flashes.

So, can this discovery lead to new non-hormonal targeted therapies for hot flashes during menopause? We sourced perspectives and reactions to this research discovery from menopause and women’s health experts, who seem optimistic about the consequences of these findings.

Barbra’s Thoughts

Barbra Hanna, DO, FACOG, NCMP who is the founder & CEO of MyMenopauseRx has spent the last few years helping women feel well, sleep well and live well with menopause. She is quite excited about the recent discoveries and believes studies like these may lead to non-hormonal treatments to help women lead better lives.

“Estrogens have an important role in every tissue of our body. And hot flashes and night sweats that are debilitating through the menopausal transition really wreak havoc on a woman’s quality of life. Yet, some women can’t or don’t want to use menopausal hormone therapy. The scientific discovery of where those hot flashes and night sweats originate from in our brain is not only fascinating but it’s going to help move science forward to improve the quality of life of so many women.”

Kim’s Thoughts

Can this new research help change society’s attitude and baked-in negative assocations toward menopause? Kim Vopni of Pelvienne Wellness believes it can. Kim is the leading go-to expert for pelvic floor exercise programs that have helped numerous women over the years deal with certain symptoms of menopause. Here are her thoughts on a compendium of reporting out of National Geographic surrounding this and other recent research on menopause.

“I was pleasantly surprised to see an entire section dedicated to vaginal health, specifically genitourinary syndrome of menopause, which is an umbrella term that covers a lot of things that I have been speaking and preaching about for many years and coming up to resistance because the word vagina is considered “inappropriate”, especially in platforms doing to do with social media.

The interesting piece about menopause is actually bringing light. The conversation around menopause is bringing light to pelvic floor disorders. They talked about pelvic floor physical therapy, which in my opinion is the most underused women’s resource that we have. I believe every woman should be seeing one from the time we’re sexually active once a year for the rest of our life, just like we see a dentist once a year for our teeth.

I also like that they did include vaginal, estrogen and the safety surrounding that. I believe and see evidence to support starting it around the time of menopause and staying on it for the rest of our life can help decrease UTIs, can help improve sex, can help with incontinence, all these things that we have thought we need to suffer with.

So, I was really delighted by that particular section. The entire article was well-informed but specific of course to the vaginal piece. I think it was well-informed and I hope that it starts to change the landscape for women going forward.”

Dr. Mindy’s Thoughts

For women in our audience seeking a little advice, how should this new research around menopause help clarify the proper steps and strategies for mitigating menopause’s worst symptoms? Dr. Mindy Pelz, a women’s health and fasting expert, and the founder of Dr. Mindy Pelz Co., reacts to National Geographic’s article and provides perspectives on menopause symptom treatment.

“I wanna highlight a couple of important parts of this article. One, everything the article talks about, the hormonal changes that are happening, are really real for women. The hot flashes, the weight gain, the trouble sleeping. Everything starts to shift after 40, and so your lifestyle needs to shift with those hormones. Things like making sure that you are intermittent fasting and adding in some…cycling in the ketogenic diet and looking at your toxic load. Those all become massively important as you go through the menopausal years.

Now the other thing that this article brings up is that we’re revisiting HRT, and I think this is a great thing. We should look at HRT, we should look at bioidenticals, and look at where the safety is for those specific medications for menopausal women. But we can’t look at medication as the only solution. We’re gonna have to pair a healthy lifestyle to it.

So the article really brought to the surface some important topics that aren’t being discussed culturally. So thank you, National Geographic, but I also wanna highlight that we do need to dive into lifestyle. What are the lifestyle changes and what’s the appropriate medication for you? There is not a one size fits all to these symptoms, and so understanding yourself and what’s gonna working with your doctor to figure out what’s best for you becomes imperative.”

Article written by Galina Mikova.

About the author

S
Sciences

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

The pharmaceutical industry is facing a significant challenge as over $300 billion in branded pharmaceutical revenue is set to lose patent protection by 2030. This revenue gap is driving the largest merger and acquisition cycle seen in a decade, with companies seeking external growth through acquisitions. This shift is impacting the entire life sciences supply chain, prompting strategic changes across the industry.

  • 01Over $300 billion in pharmaceutical revenue is at risk due to patent expirations by 2030.
  • 02Big Pharma is engaging in an aggressive cycle of mergers and acquisitions.
  • 03The acquisitions are reshaping the life sciences supply chain.

Jun 29, 2026

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences has initiated a Phase I clinical study of an oral solid dose formulation designed using AI, cleared by the UK's MHRA and conducted at the company's UK facility. The trial—built on machine learning algorithms from partner Intrepid Labs and Quotient's Translational Pharmaceutics platform—aims to validate AI as a direct contributor to formulation design rather than just an upstream analytical tool. Benchling characterizes the broader moment as biotech entering a "builder phase," in which leading organizations embed AI capability at the bench level rather than running isolated pilots.

  • 01Quotient Sciences has dosed healthy volunteers in a Phase I study it describes as the first clinical evaluation of an AI-designed oral formulation, following approval from the UK's MHRA.
  • 02The formulation was developed using advanced machine learning algorithms from Intrepid Labs, integrated with Quotient Sciences' Translational Pharmaceutics platform.
  • 03Benchling identifies a sector-wide shift toward embedding AI capability directly at the bench, moving beyond isolated pilots to structural adoption across biotech R&D.

Jun 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

S
Sciences

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512